Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated June 10, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 66,000 people across 80 countries. The filing details transactions executed under a programme initiated on May 6, 2024, which is part of a broader 12-month repurchase plan starting February 6, 2024.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities rather than operational financial performance. Key metrics include:
- Total Repurchase Programme Cap: Up to DKK 20 billion over 12 months (starting February 6, 2024).
- Specific Sub-Programme (May 6 - August 5, 2024): Up to DKK 2.2 billion.
- Cumulative Repurchases (as of June 7, 2024): 9,520,795 B shares.
- Average Purchase Price (Cumulative): DKK 866.73 per B share.
- Total Transaction Value (Cumulative): DKK 8,251,969,609.
- Treasury Shares Held: 10,886,359 B shares (0.2% of share capital).
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Recent Activity
Since the last announcement on June 3, 2024, the company executed four additional transactions between June 3 and June 7, 2024. The average purchase price for these recent transactions ranged from DKK 921.24 to DKK 978.72, indicating an upward trend in share price during this specific window. The accumulated number of shares repurchased under the specific May 6 programme reached 786,545 shares with a value of DKK 724,234,837.
Guidance, Outlook, and Risks
Management expects to continue repurchasing B shares up to the DKK 20 billion limit during the 12-month period beginning February 6, 2024. The programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules. The filing does not contain specific operational guidance, risk factors, or contingencies beyond the standard regulatory framework for share buybacks.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 20 billion total programme (approx. DKK 11.75 billion remaining as of June 7).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average purchase price of DKK 978.72.
- Review the full transaction history on novonordisk.com for granular daily data.
- Check the total share capital count (4,465,000,000 shares) to monitor dilution or concentration effects.